This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McCrindle, B. W. Search for Related Content PubMed PubMed Citation Articles by McCrindle, B. W.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:982.)
© 2007 American Heart Association, Inc.

Editorials

Summary of the American Heart Association’s Scientific Statement on Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents

Brian W. McCrindle for the Writing Group

From the Division of Cardiology, Department of Pediatrics, University of Toronto, The Hospital for Sick Children, Toronto, Ontario, Canada.

Correspondence to Dr Brian McCrindle, The Hospital for Sick Children, 555 University Ave, Toronto, Ontario, Canada M5G 1X8. E-mail brian.mccrindle@sickkids.ca

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Drug therapy of lipid abnormalities in children and adolescents has been surrounded with controversy. Much of the debate is about the evidence that intervening in asymptomatic youth will reduce disease morbidity or mortality in adulthood. There is also particular concern that the increasing prevalence of lipid abnormalities associated with the epidemic of pediatric obesity will lead to a generation of children taking long-term medication for lifestyle-related issues. The Writing Group, therefore, sought to examine the current state of evidence and guidelines and to provide clarifications and modifications, which are detailed in their Scientific Statement.¹

See Circulation. 2007;115:1948–1967

	Imperative for Intervention

 
A substantial body of evidence now exists to assert that the atherosclerotic process begins in childhood and is associated with the recognized cardiovascular risk factors. Pathologic studies, such as the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Study, have shown strong associations with the extent of early atherosclerotic lesions and levels of risk factors, including lipid abnormalities. An important observation from pathology studies has been the geometric association between increasing number of risk factors and the extent of lesions, which has important implications in view of the increasing prevalence of risk factor clustering associated with obesity and the metabolic syndrome. Population-based studies, such as the Bogalusa Heart Study and the Muscatine Study, find increasing trends in adiposity and associated risk factors in youth, and that both risk factors and obesity track into adulthood. These studies demonstrate associations between lipid abnormalities and noninvasively measured markers of early atherosclerosis. Recent clinical trials have shown . . . [Full Text of this Article]

This article has been cited by other articles:

				P. Velasquez-Mieyer, C. P. Neira, R. Nieto, and P. A. Cowan Review: Obesity and cardiometabolic syndrome in children Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 61 - 81. [Abstract] [PDF]